Annual report pursuant to Section 13 and 15(d)

Note 25 - Selected Quarterly Financial Data (Unaudited)

v3.8.0.1
Note 25 - Selected Quarterly Financial Data (Unaudited)
12 Months Ended
Dec. 31, 2017
Notes to Financial Statements  
Quarterly Financial Information [Text Block]
2
5
.
Selected Quarterly Financial Data (Unaudited)
 
Quarterly financial information for fiscal
201
7
and
2016
are presented in the following table, in thousands, except per share data. Certain revenue and expense amounts in the years ended
December 31, 2017
and
2016
have been reclassified to discontinued operations. See Note
3.
 
   
For the Quarter Ending
 
   
March 31
   
June 30
   
September 30
   
December 31
 
2017:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tc99m tilmanocept sales revenue
  $
    $
    $
    $
 
Tc99m tilmanocept license revenue
   
     
100
     
     
 
Tc99m tilmanocept royalty revenue
   
     
     
     
9
 
Grant and other revenue
   
580
     
512
     
224
     
386
 
Gross profit
   
580
     
612
     
224
     
391
 
Operating expenses
   
3,728
     
5,435
     
2,609
     
3,912
 
Loss from operations
   
(3,148
)
   
(4,823
)
   
(2,385
)
   
(3,521
)
Loss before income taxes
   
(4,319
)
   
(4,783
)
   
(2,317
)
   
(6,371
)
Benefit from
(provision for) income taxes
   
1,454
     
1,631
     
776
     
201
 
Loss from continuing operations
   
(2,865
)
   
(3,152
)
   
(1,541
)
   
(6,170
)
Gain (loss) from discontinued operations, net of tax
   
88,446
     
(2,036
)
   
151
     
2,112
 
Net
income (loss) attributable to common stockholders
   
85,581
     
(5,188
)
   
(1,390
)
   
(4,058
)
Loss per common share (basic)
(1)
:
                               
Continuing operations
  $
(0.02
)
  $
(0.02
)
  $
(0.01
)
  $
(0.04
)
Discontinued operations
  $
0.55
    $
(0.01
)
  $
    $
0.01
 
Attributable to common stockholders
  $
0.53
    $
(0.03
)
  $
(0.01
)
  $
(0.03
)
Loss per common share (diluted)
(1)
:
                               
Continuing operations
  $
(0.02
)
  $
(0.02
)
  $
(0.01
)
  $
(0.04
)
Discontinued operations
  $
0.54
    $
(0.01
)
  $
    $
0.01
 
Attributable to common stockholders
  $
0.52
    $
(0.03
)
  $
(0.01
)
  $
(0.03
)
                                 
2016:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tc99m tilmanocept sales revenue
  $
9
    $
4
    $
18
    $
9
 
Tc99m tilmanocept license revenue
   
254
     
246
     
1,296
     
 
Grant and other revenue
   
686
     
917
     
511
     
1,022
 
Gross profit
   
947
     
1,166
     
1,821
     
975
 
Operating expenses
   
4,705
     
3,407
     
2,731
     
4,215
 
Loss from operations
   
(3,758
)
   
(2,241
)
   
(910
)
   
(3,240
)
Loss from continuing operations
   
(2,682
)
   
(817
)
   
(1,761
)
   
(2,118
)
Gain (loss) from discontinued operations, net of tax
   
(1,004
)
   
(5,865
)
   
1,702
     
(1,764
)
Net loss attributable to common stockholders
   
(3,686
)
   
(6,682
)
   
(59
)
   
(3,882
)
Loss per common share (basic and diluted)
(1)
:
                               
Continuing operations
  $
(0.02
)
  $
(0.01
)
  $
(0.01
)
  $
(0.01
)
Discontinued operations
  $
0.00
    $
(0.03
)
  $
0.01
    $
(0.02
)
Attributable to common stockholders
  $
(0.02
)
  $
(0.04
)
  $
(0.00
)
  $
(0.03
)
 
 
(
1
)
Net loss per share is computed independently for each of the quarters presented. Therefore the sum of the quarterly per-share calculations will
not
necessarily equal the annual per share calculation.